Ocean Biomedical

Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL

Retrieved on: 
Thursday, March 28, 2024
Conditional sentence, Infection, JV, Ocean Biomedical, Risk, Patient, Research, Cancer, HBV, Neoplasm, Therapy, Liver, Safety

The clinical safety of this novel mechanism of action, via checkpoint modification, are supported by the these first data presented at APASL.

Key Points: 
  • The clinical safety of this novel mechanism of action, via checkpoint modification, are supported by the these first data presented at APASL.
  • Treatments for chronic HBV are in high demand and could capture an estimated global market of $6.5+ billion by 2032 .
  • These safety data are another major milestone for our JV partner, Virion, and we look forward to seeing additional safety, and immunological data, at an upcoming meeting.
  • Ocean is pleased to partner with Virion in bringing this technology to patients worldwide and we look forward to helping accelerate this, and other programs, in development.”

Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

Retrieved on: 
Tuesday, March 5, 2024
MRK, Hospital, News, FOLFIRINOX, Growth, AbbVie, PR, Neutrophil, Poster, Diagnosis, Pancreatic cancer, HBV, Incidence, Cancer, TME, Hepatology, Interleukin, Therapy, Prostate cancer, Liver, Immune system, Partnership, Merck & Co., AIO, PSMA, Inflammation, Safety, TILS, GPCR, Tumor microenvironment, Research, Medication, PALM, ABBV, Merck, Macrophage, Blood, FDA, TSX, Food, Ageing, Pembrolizumab, Pancreatic Cancer Action Network, Government, Prevalence, Ocean Biomedical, LAVA, PDAC, Patient, MHRA, Disease, ONC, PEI, Pharmaceutical industry

Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth.

Key Points: 
  • Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth.
  • The incidence is significantly higher in the geriatric population above 65 years of age compared to other types of cancers.
  • A report from Fortune Business Insights said that: “the pancreatic cancer treatment market size is projected to grow to USD 6.85 billion by 2029, exhibiting a CAGR of 15.7% during 2022-2029.
  • Companies engaged in manufacturing cancer drugs have increased their focus on R&D activities to develop new drugs for pancreatic cancer treatment.

Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting

Retrieved on: 
Thursday, February 29, 2024
HBV, MD, Immunotherapy, EST, Hepatology, Safety, Ocean Biomedical, Therapy, Gastrointestinal disease, Patient, Liver, Research

The late breaker presentation will highlight the safety data observed, to date, in the ongoing Phase 1B clinical trial of VRON-0200.

Key Points: 
  • The late breaker presentation will highlight the safety data observed, to date, in the ongoing Phase 1B clinical trial of VRON-0200.
  • “This accepted abstract highlights Virion’s commitment to finding a functional cure for chronically HBV-infected patients - and the first-ever human data for a genetically encoded checkpoint modifier T cell vaccine of any kind.
  • VRON-0200 is uniquely developed to stimulate a patient’s own immune response to the virus.
  • Department of Medicine and Therapeutics, and Institute of Digestive Disease, Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong

Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody

Retrieved on: 
Tuesday, December 5, 2023
Cancer research, Ocean Biomedical, Immunotherapy, Neoplasm, University, IND, Breast cancer, Antibody, Research, PD-1, Glioblastoma, Apoptosis, Yale University, NETS, TKI, Cancer, CTLA4, Neutrophil extracellular traps, Colorectal cancer, Journal, PTEN, BioRxiv, Growth, McGill University, Publication, Immunity, Science, Pharmaceutical industry

PROVIDENCE, Rhode Island, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that its Scientific Co-founder, Jack A. Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple negative breast cancer. The groundbreaking discoveries by a team led by Dr. William Muller at McGill University and in collaboration with Dr. Elias demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs which block T cells from contacting and killing the breast cancer tumor. Additionally, the study provides further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in reversing this process and suppressing breast cancer tumor growth.

Key Points: 
  • Additionally, the study provides further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in reversing this process and suppressing breast cancer tumor growth.
  • This groundbreaking paper deepens the understanding of how CHI3L1 inhibits the body’s natural ability to fight breast cancer tumors.
  • Although these findings were defined in NSCLC, they have potential effectiveness in other EGFR-mutation driven cancers including Glioblastoma and Colon cancer.
  • Prior research has established that elevated Chi3L1 levels are associated with many cancers, including glioblastoma, and may be targeted therapeutically.

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Retrieved on: 
Wednesday, November 29, 2023
Ocean Biomedical, Form, LP, Bank statement, Cryptocurrency

As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-Q.

Key Points: 
  • As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-Q.
  • In accordance with this interpretation, Ocean Biomedical has determined to restate its consolidated financial statements as of and for the quarters ended March 31, 2023 and June 30, 2023.
  • Nasdaq indicated that the Company must: (i) no later than January 22, 2024, submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before May 20, 2024, file the delinquent Form10-Q.
  • The Company intends to file the delinquent Form 10-Q as soon as practicable.

Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection

Retrieved on: 
Thursday, October 26, 2023
Science, Ocean Biomedical, Research, Hepatitis, Therapy, Patient, HBV, Pharmaceutical industry, Virus

VRON-0200, a first-in-class treatment, using one of Virion’s proprietary checkpoint modifiers, was specifically designed to enhance and broaden a patient’s own immune response.

Key Points: 
  • VRON-0200, a first-in-class treatment, using one of Virion’s proprietary checkpoint modifiers, was specifically designed to enhance and broaden a patient’s own immune response.
  • This novel mechanism of action may help overcome one of the key problems faced in treating chronic HBV—immune exhaustion.
  • The international, first-in-human VRON-0200 Phase 1b study is currently enrolling patients in Hong Kong and New Zealand, with additional sites planned in the United States.
  • “We are thrilled to be partnering with Virion as they advance this important science into its clinical testing phase.

Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection

Retrieved on: 
Thursday, October 26, 2023
Ocean Biomedical, Joint venture, Hepatitis, Therapy, Patient, HBV, Vaccine, Pharmaceutical industry, Virus

PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean Biomedical, Inc. (NASDAQ: OCEA ), today announced that the first patients have been dosed in the Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus (HBV) infection.

Key Points: 
  • PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean Biomedical, Inc. (NASDAQ: OCEA ), today announced that the first patients have been dosed in the Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus (HBV) infection.
  • VRON-0200, a first-in-class treatment, using one of Virion's proprietary checkpoint modifiers, was specifically designed to enhance and broaden a patient's own immune response.
  • This novel mechanism of action may help overcome one of the key problems faced in treating chronic HBV - immune exhaustion.
  • The international, first-in-human VRON-0200 Phase 1b study is currently enrolling patients in Hong Kong and New Zealand, with additional sites planned in the United States.

Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis

Retrieved on: 
Tuesday, October 24, 2023
Ocean Biomedical, Disease, Artemisinin, Malaria, Doctor of Philosophy, Research, Pharmaceutical industry

Providence, RI, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ), today announced that its Chief Scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk Medical Research Trust Transformational Award to advance a new class of anti-malarial drug candidates.

Key Points: 
  • Providence, RI, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ), today announced that its Chief Scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk Medical Research Trust Transformational Award to advance a new class of anti-malarial drug candidates.
  • Dr. Kurtis’ malaria drug program stems from his groundbreaking malaria vaccine research , targeting a critical stage of the malaria cycle.
  • This program, which includes a therapeutic small molecule drug candidate for treating severe malaria, and a therapeutic antibody for short term malaria prevention, is designed to address the growing resistance to the current best-in-class Artemisinin-based medicines.
  • “It has become increasingly apparent that a new, more effective class of anti-malarials is needed, especially to combat severe malaria,” said Dr. Jonathan Kurtis, one of Ocean’s Scientific Co-Founders.

Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Research, IND, Death, Disease, Therapy, Hepatitis, Person, HBV, Ocean Biomedical, Infection, JV, Patient, VIR, Pharmaceutical industry, Virus

This study will also inform and expedite the other IND-enabling activities in the JV’s pipeline, including VRON-0300, for the treatment of patients with advanced solid tumors.

Key Points: 
  • This study will also inform and expedite the other IND-enabling activities in the JV’s pipeline, including VRON-0300, for the treatment of patients with advanced solid tumors.
  • Chronic HBV remains a global health issue with a high unmet medical need as there is no cure available.
  • On October 11, 2023, Ocean acquired a 50% ownership interest in Virion Therapeutics through a joint venture that includes all current and future Virion development programs.
  • Ocean is pleased to partner with Virion in bringing this high-need, high-value treatment – aiming for a functional cure – to patients with chronic HBV around the world.”

Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund

Retrieved on: 
Wednesday, October 4, 2023
Trigger, Polar, Side letter (contract law), Side letter, Sales, Ocean Biomedical, Stock dilution, Side, Ocean, Fibrosis, VWAP, Biomedicine, Commercial property

Providence, RI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announces that the company and Polar Multi-Strategy Master Fund (Polar) entered into a Side Letter related to the Forward Purchase Agreement entered into in February 2023.

Key Points: 
  • Providence, RI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announces that the company and Polar Multi-Strategy Master Fund (Polar) entered into a Side Letter related to the Forward Purchase Agreement entered into in February 2023.
  • The Seller VWAP Trigger Event does not prescribe when, or at what price, Polar can elect to sell shares under the agreement.
  • Ocean Biomedical did not pay Polar any new fee or provide any other new consideration for the entering into the Side Letter, nor did the Side Letter result in a dilutive offering.
  • “Ocean Biomedical is pleased that Polar is a stockholder of the company.